ClinicalTrials.Veeva

Menu
F

Floridian Clinical Research | Miami Lakes, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Islatravir
Lenacapavir
Semaglutide
Efinopegdutide
MK-6024
VIR-2218
RTA 901
GS-1720
Brenipatide
Tirzepatide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

30 of 60 total trials

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatit...

Active, not recruiting
Metabolic Dysfunction-associated Steatotic Liver Disease
Non-alcoholic Fatty Liver Disease
Combination Product: Efinopegdutide
Combination Product: Placebo

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers...

Enrolling
End-Stage Renal Disease
Chronic Kidney Failure
Drug: MK-2828

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in...

Enrolling
Metabolic Dysfunction-Associated Steatotic Liver Disease
Drug: Tirzepatide
Drug: Placebo

The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-asso...

Active, not recruiting
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Drug: Placebo
Drug: LY3849891

The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high d...

Enrolling
Metabolic Dysfunction-associated Steatohepatitis
Drug: Placebo
Drug: ECC4703

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo pl...

Enrolling
Bipolar Disorder
Drug: Brenipatide
Drug: Placebo

This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying th...

Enrolling
Depressive Disorder, Major
Drug: Placebo
Drug: Brenipatide

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get r...

Enrolling
Renal Impairment
Renal Insufficiency Chronic
Drug: LY3841136

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants wit...

Enrolling
Healthy
Rheumatoid Arthritis (RA)
Drug: LY4213663
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10...

Enrolling
Type 2 Diabetes (T2DM)
Metabolic Syndrome (MetS)
Drug: Obicetrapib 10 mg
Other: Placebo

The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to pla...

Active, not recruiting
Influenza
Combination Product: CD388 Injection
Combination Product: Placebo

The goal of this clinical study is to learn if giving repeated annual doses of the experimental drug CD388 is safe and how the body reacts to it in h...

Active, not recruiting
Healthy Participants
Combination Product: CD388 Injection

The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.

Active, not recruiting
Herpes Zoster
Biological: Shingrix
Biological: Placebo

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and bo...

Enrolling
Overweight or Obesity and Elevated Liver Fat
Drug: Placebo
Drug: Maridebart cafraglutide

This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a do...

Enrolling
Atherosclerotic Cardiovascular Disease
Atherosclerotic Cardiovascular Disease in Patients With ESKD
Drug: Placebo
Drug: CSL300

In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be admin...

Enrolling
Hepatic Impairment
Cirrhosis
Drug: VIR-2218
Drug: VIR-3434

The purpose of this study is to evaluate the effect and safety of orforglipron once daily in participants with Fontaine II peripheral arterial diseas...

Enrolling
Peripheral Arterial Disease
Drug: Orforglipron
Drug: Placebo

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with hea...

Active, not recruiting
Chronic Heart Failure
Drug: JTT-861 Capsules
Drug: Placebo Capsules

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Lilly logo
Gilead Sciences logo
Amgen logo
Moderna logo
C
Boehringer Ingelheim logo
Janssen (J&J Innovative Medicine) logo
Novo Nordisk logo
Reata Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems